by Stephen Levin
One of the most challenging aspects of treating cardiovascular disease is that, viewed as a whole, heart disease is like playing with a water balloon: you push on one area...
Heart failure is a huge growing market in which devices are looking to succeed where drugs have provided only limited benefit. Paracor is taking on the role of David In a field dominated by the Goliaths in cardiac rhythm management and their powered devices. The company is betting that its strategy to focus first on a mechanical approach offers a better alternative for many patients not well-served by current therapies.
by Stephen Levin
One of the most challenging aspects of treating cardiovascular disease is that, viewed as a whole, heart disease is like playing with a water balloon: you push on one area...
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.